On January 6, 2022, Reynolds, Dominic; Seiler, Michael W.; Agrawal, Anant A.; Vaillancourt, Frederic; Smith, Peter; Hopper, Allen T.; Prajapati, Sudeep; Vyskocil, Stepan published a patent.HPLC of Formula: 2089292-88-4 The title of the patent was Preparation of 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids for the treatment of proliferative diseases. And the patent contained the following:
The disclosure relates to the title compounds I, wherein A and B are independently (un)substituted heterocyclyl and heteroaryl; L1 and L2 are independently absent, O, CO, etc.; X and Y are independently N and CR6; R2 and R3 are independently C1-6 alkyl, halo, CN, etc.; R6 is H, halo, CN, etc.; m = 0-1; N = 0-2; and pharmaceutically acceptable salts thereof, solvates, hydrates, tautomers, and stereoisomers thereof, that modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof. Example compound II was prepared by a multistep procedure (procedure given). Compounds described herein were used to modulate RNA transcript abundance in cells (data given for representative compounds I). The experimental process involved the reaction of 5-Bromo-2-methyl-2H-pyrazolo[3,4-c]pyridine(cas: 2089292-88-4).HPLC of Formula: 2089292-88-4
The Article related to indazolyl piperidinylnaphthyridine preparation nucleic acid mrna splicing modulator antiproliferative, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.HPLC of Formula: 2089292-88-4
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics